AKTX

Globally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicing into future Phase 1 First-in-Human trial TAMPA, Fla.

Consolidated closing of recently announced $5.5 million PIPE led by existing investors, combined with an additional $2.8 million in proceeds from warrant exercises, results in approximately $8.3 million of capital received in Q2 2026, supporting future potential value inflection points TAMPA, Fla.

Discussion highlights growing importance on novel ADC payloads, and Akari’s ASCO data in KRAS-driven cancers and future potential Access the Akari CEO Corner here TAMPA, Fla. and LONDON, June 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company

CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers Watch the “What This Means” video here TAMPA, Fla. and LONDON, May 28, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company

An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activity against KRAS G12D and G12C- driven pancreatic cancer models Data supports the broader applicability of targeting RNA splicing to attack difficult-to-treat KRAS-driven

TAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the successful pricing of a private placement financing round.

Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here TAMPA, Fla. and LONDON, May 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody

Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications TAMPA, Fla. and LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody

Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancer Approval strengthens Akari’s global intellectual property across all major markets and supports advancement of AKTX-101 and ADC pipeline TAMPA, Fla.

Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current Phase 1 plan Publication to be made available online on May 21, 2026 at 5:00 PM ET TAMPA, Fla. and LONDON, April 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc

Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor resistance Preclinical data support advancement of AKTX-101 into Phase 1 studies in a rapidly